by Anne Trafton
The top two panels show tumors produced by cancer cells. The outer ring of cells (blue) has enough oxygen to survive, but not as much oxygen reaches the inner cells. At top right, tumor cells lack the SHMT2 gene and are unable to survive in this central region, as indicated by the pink stain that marks a protein produced during cell death. At top left, the cells express high levels of SHMT2, allowing some of them to survive, indicated by the blue clusters of cells. The bottom two panels are magnifications of the central tumor regions. Credit: Courtesy of the researchers
Biologists at MIT and the Whitehead Institute for Biomedical Research have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors.
The study, led by researchers from the Whitehead Institute and MIT's Koch Institute for Integrative Cancer Research, found that a subset of glioblastoma tumor cells is dependent on a particular enzyme that breaks down the amino acid glycine. Without this enzyme, toxic metabolic byproducts build up inside the tumor cells, and they die.
Blocking this enzyme in glioblastoma cells could offer a new way to combat such tumors, says Dohoon Kim, a postdoc at the Whitehead Institute and lead author of the study, which appears in the April 8 online edition of Nature.
David Sabatini, a professor of biology at MIT and member of the Whitehead Institute, is the paper's senior author. Matthew Vander Heiden, the Eisen and Chang Career Development Associate Professor of Biology and a member of the Koch Institute, also contributed to the research, along with members of his lab.
GLDC caught the researchers' attention as they investigated diseases known as "inborn errors of metabolism," which occur when cells are missing certain metabolic enzymes. Many of these disorders specifically affect brain development; the most common of these is phenylketonuria, marked by an inability to break down the amino acid phenylalanine. Such patients must avoid eating phenylalanine to prevent problems such as intellectual disability and seizures.
Loss of GLDC produces a disorder called nonketotic hyperglycinemia, which causes glycine to build up in the brain and can lead to severe mental retardation. GLDC is also often overactive in certain cells of glioblastoma, the most common and most aggressive type of brain tumor found in humans.
The researchers found that GLDC, which breaks down the amino acid glycine, is overexpressed only in glioblastoma cells that also have high levels of a gene called SHMT2, which converts the amino acid serine into glycine. Those cells are so dependent on GLDC that when they lose it, they die.
Further investigation revealed that SHMT2 is expressed most highly in cancer cells that live in so-called ischemic regions—areas that are very low in oxygen and nutrients. These regions are often found at the center of tumors, which are inaccessible to blood vessels. It turns out that in this low-oxygen environment, SHMT2 gives cells a survival edge because it can indirectly influence the activity of an enzyme called PKM2, which is part of the cell's machinery for breaking down glucose.
Regulation of PKM2 can impact whether cells can generate the material to build new cancer cells, but the same regulation also affects the consumption of oxygen—a scarce resource in ischemic regions.
"Cells that have high SHMT2 activity have low PKM2 activity, and consequently low oxygen-consumption rates, which makes them better suited to survive in the ischemic tumor microenvironment," Kim says.
However, this highly active SHMT2 also produces a glut of glycine, which the cell must break down using GLDC. Without GLDC, glycine enters a different metabolic pathway that generates toxic products that accumulate and kill the cell.
The finding also raises the possibility that these GLDC-dependent cells could be killed with drugs that block GLDC activity, according to the researchers, who are now seeking potential drug compounds that could do just that.
Explore further: Novel regulatory mechanism for cell division found
More information: SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance, Nature (2015) DOI: 10.1038/nature14363
Medical Xpress on facebook
Related Stories
Major genetic study links liver disease gene to bladder cancer
A University of Colorado Cancer Center study published today in Journal of the National Cancer Institute (with related research being presented this weekend at the American Association for Cancer Research Annual Conference 2014) ...
Novel regulatory mechanism for cell division found
A protein kinase or enzyme known as PKM2 has proven to control cell division, potentially providing a molecular basis for tumor diagnosis and treatment.
Researchers identify protein pathway involved in brain tumor stem cell growth
Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification ...
Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.
Selectively inhibiting PKM2 starves cancer cells
Crippling a protein that allows cancer cells to grow when oxygen is scarce causes tumors to regress, according to a study published online on January 23 in the Journal of Experimental Medicine.
Recommended for you
No association between lung cancer risk in women and reproductive history or hormone use
The Women's Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for ...
Tumor cells that mimic blood vessels could help breast cancer spread to other sites
Imitation may be the sincerest form of flattery, but it can also have deadly consequences, at least when it comes to tumor cells.
Melanoma surgery delays are common for Medicare patients
One in five Medicare patients with melanoma experience delays in getting surgery, a Yale study found. The research was published April 8 in JAMA Dermatology.
MRI screening program for individuals at high risk of pancreatic cancer
A magnetic resonance imaging (MRI)-based screening program for individuals at high risk of pancreatic cancer identified pancreatic lesions in 16 of 40 (40 percent) of patients, of whom 5 five underwent surgery, according ...
A digital field guide to cancer cells
Scientists are mapping the habits of cancer cells, turn by microscopic turn.
Graduate student diagnosed with brain tumor dives into the data
In 2007, Steven Keating had his brain scanned out of sheer curiosity.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
by Anne Trafton
The top two panels show tumors produced by cancer cells. The outer ring of cells (blue) has enough oxygen to survive, but not as much oxygen reaches the inner cells. At top right, tumor cells lack the SHMT2 gene and are unable to survive in this central region, as indicated by the pink stain that marks a protein produced during cell death. At top left, the cells express high levels of SHMT2, allowing some of them to survive, indicated by the blue clusters of cells. The bottom two panels are magnifications of the central tumor regions. Credit: Courtesy of the researchers
Biologists at MIT and the Whitehead Institute for Biomedical Research have discovered a vulnerability of brain cancer cells that could be exploited to develop more-effective drugs against brain tumors.
The study, led by researchers from the Whitehead Institute and MIT's Koch Institute for Integrative Cancer Research, found that a subset of glioblastoma tumor cells is dependent on a particular enzyme that breaks down the amino acid glycine. Without this enzyme, toxic metabolic byproducts build up inside the tumor cells, and they die.
Blocking this enzyme in glioblastoma cells could offer a new way to combat such tumors, says Dohoon Kim, a postdoc at the Whitehead Institute and lead author of the study, which appears in the April 8 online edition of Nature.
David Sabatini, a professor of biology at MIT and member of the Whitehead Institute, is the paper's senior author. Matthew Vander Heiden, the Eisen and Chang Career Development Associate Professor of Biology and a member of the Koch Institute, also contributed to the research, along with members of his lab.
GLDC caught the researchers' attention as they investigated diseases known as "inborn errors of metabolism," which occur when cells are missing certain metabolic enzymes. Many of these disorders specifically affect brain development; the most common of these is phenylketonuria, marked by an inability to break down the amino acid phenylalanine. Such patients must avoid eating phenylalanine to prevent problems such as intellectual disability and seizures.
Loss of GLDC produces a disorder called nonketotic hyperglycinemia, which causes glycine to build up in the brain and can lead to severe mental retardation. GLDC is also often overactive in certain cells of glioblastoma, the most common and most aggressive type of brain tumor found in humans.
The researchers found that GLDC, which breaks down the amino acid glycine, is overexpressed only in glioblastoma cells that also have high levels of a gene called SHMT2, which converts the amino acid serine into glycine. Those cells are so dependent on GLDC that when they lose it, they die.
Further investigation revealed that SHMT2 is expressed most highly in cancer cells that live in so-called ischemic regions—areas that are very low in oxygen and nutrients. These regions are often found at the center of tumors, which are inaccessible to blood vessels. It turns out that in this low-oxygen environment, SHMT2 gives cells a survival edge because it can indirectly influence the activity of an enzyme called PKM2, which is part of the cell's machinery for breaking down glucose.
Regulation of PKM2 can impact whether cells can generate the material to build new cancer cells, but the same regulation also affects the consumption of oxygen—a scarce resource in ischemic regions.
"Cells that have high SHMT2 activity have low PKM2 activity, and consequently low oxygen-consumption rates, which makes them better suited to survive in the ischemic tumor microenvironment," Kim says.
However, this highly active SHMT2 also produces a glut of glycine, which the cell must break down using GLDC. Without GLDC, glycine enters a different metabolic pathway that generates toxic products that accumulate and kill the cell.
The finding also raises the possibility that these GLDC-dependent cells could be killed with drugs that block GLDC activity, according to the researchers, who are now seeking potential drug compounds that could do just that.
Explore further: Novel regulatory mechanism for cell division found
More information: SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance, Nature (2015) DOI: 10.1038/nature14363
Medical Xpress on facebook
Related Stories
Major genetic study links liver disease gene to bladder cancer
A University of Colorado Cancer Center study published today in Journal of the National Cancer Institute (with related research being presented this weekend at the American Association for Cancer Research Annual Conference 2014) ...
Novel regulatory mechanism for cell division found
A protein kinase or enzyme known as PKM2 has proven to control cell division, potentially providing a molecular basis for tumor diagnosis and treatment.
Researchers identify protein pathway involved in brain tumor stem cell growth
Glioblastomas are a highly aggressive type of brain tumor, with few effective treatment options. Moffitt Cancer Center researchers are one step closer to understanding glioblastoma development following the identification ...
Glioblastoma: Study ties three genes to radiation resistance in recurrent tumors
A new study identifies three genes that together enable a lethal form of brain cancer to recur and progress after radiation therapy.
Selectively inhibiting PKM2 starves cancer cells
Crippling a protein that allows cancer cells to grow when oxygen is scarce causes tumors to regress, according to a study published online on January 23 in the Journal of Experimental Medicine.
Recommended for you
No association between lung cancer risk in women and reproductive history or hormone use
The Women's Health Initiative Studies, a large prospective study of lung cancer, found no strong associations between lung cancer risk and a wide range of reproductive history variables and only revealed weak support for ...
Tumor cells that mimic blood vessels could help breast cancer spread to other sites
Imitation may be the sincerest form of flattery, but it can also have deadly consequences, at least when it comes to tumor cells.
Melanoma surgery delays are common for Medicare patients
One in five Medicare patients with melanoma experience delays in getting surgery, a Yale study found. The research was published April 8 in JAMA Dermatology.
MRI screening program for individuals at high risk of pancreatic cancer
A magnetic resonance imaging (MRI)-based screening program for individuals at high risk of pancreatic cancer identified pancreatic lesions in 16 of 40 (40 percent) of patients, of whom 5 five underwent surgery, according ...
A digital field guide to cancer cells
Scientists are mapping the habits of cancer cells, turn by microscopic turn.
Graduate student diagnosed with brain tumor dives into the data
In 2007, Steven Keating had his brain scanned out of sheer curiosity.
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment